Eli Lilly's COVID-19 antibody sales crater as variants, vaccines take a toll

Greater vaccine access and pesky coronavirus variants are taking the wind out of Eli Lilly’s COVID-19 antibodies.

That was clear in the company second-quarter results, which reflected an expeditious drop in Lilly’s antibody sales over the past three months.

Lilly’s COVID-19 antibodies raked in $148.9 million during the quarter, an 82% drop from the $810.1 million the drugs generated during the first quarter this year. That includes sales of bamlanivimab, plus Lilly’s combo treatment that pairs that drug with etesevimab.